Active surveillance for low-risk bladder cancer

Albert Tiu, Lawrence C. Jenkins, Mark S. Soloway

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Most newly diagnosed bladder cancers present as non-muscle invasive bladder cancer (NMIBC). NMIBC is a heterogeneous disease with varying treatment options, follow-up schedules, and oncologic outcomes. We sought to review the role of active surveillance for low risk bladder cancer in the literature. Methods: A PubMed search was performed using the following keywords: active surveillance, low risk, bladder, transurethral resection of bladder tumor, cost, and quality of life. Relevant articles were reviewed and utilized. Results: Low-risk bladder cancer-defined as pTa low-grade papillary tumors-is the type of NMIBC with the most favorable oncologic outcome and which almost never progresses to muscle invasive disease or metastasizes. Bladder cancer has the highest per patient treatment costs of all cancers. One of the reasons is the high rate of recurrence. Patients with low-grade bladder tumors often experience a recurrence after primary transurethral resection. Many patients undergo multiple resections in the hospital. Conclusions: Appropriately selected patients with recurrent low-risk bladder cancer could be managed with either office fulguration or cystoscopic surveillance. Active surveillance for patients with low-risk bladder cancer avoids or delays the surgical and anesthetic risks of a TURBT, thus optimizing quality of life without compromising the patient's risk of cancer progression.

Original languageEnglish
JournalUrologic Oncology: Seminars and Original Investigations
Volume32
Issue number1
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Quality of Life
Recurrence
Neoplasms
PubMed
Health Care Costs
Anesthetics
Appointments and Schedules
Urinary Bladder
Costs and Cost Analysis
Muscles

Keywords

  • Active surveillance
  • Bladder cancer
  • Cost
  • Low risk
  • Quality of life
  • Transurethral resection of bladder tumor

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Active surveillance for low-risk bladder cancer. / Tiu, Albert; Jenkins, Lawrence C.; Soloway, Mark S.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 32, No. 1, 01.01.2014.

Research output: Contribution to journalArticle

Tiu, Albert ; Jenkins, Lawrence C. ; Soloway, Mark S. / Active surveillance for low-risk bladder cancer. In: Urologic Oncology: Seminars and Original Investigations. 2014 ; Vol. 32, No. 1.
@article{73641df7cc8f4a5cbc063bbafa302ddf,
title = "Active surveillance for low-risk bladder cancer",
abstract = "Background: Most newly diagnosed bladder cancers present as non-muscle invasive bladder cancer (NMIBC). NMIBC is a heterogeneous disease with varying treatment options, follow-up schedules, and oncologic outcomes. We sought to review the role of active surveillance for low risk bladder cancer in the literature. Methods: A PubMed search was performed using the following keywords: active surveillance, low risk, bladder, transurethral resection of bladder tumor, cost, and quality of life. Relevant articles were reviewed and utilized. Results: Low-risk bladder cancer-defined as pTa low-grade papillary tumors-is the type of NMIBC with the most favorable oncologic outcome and which almost never progresses to muscle invasive disease or metastasizes. Bladder cancer has the highest per patient treatment costs of all cancers. One of the reasons is the high rate of recurrence. Patients with low-grade bladder tumors often experience a recurrence after primary transurethral resection. Many patients undergo multiple resections in the hospital. Conclusions: Appropriately selected patients with recurrent low-risk bladder cancer could be managed with either office fulguration or cystoscopic surveillance. Active surveillance for patients with low-risk bladder cancer avoids or delays the surgical and anesthetic risks of a TURBT, thus optimizing quality of life without compromising the patient's risk of cancer progression.",
keywords = "Active surveillance, Bladder cancer, Cost, Low risk, Quality of life, Transurethral resection of bladder tumor",
author = "Albert Tiu and Jenkins, {Lawrence C.} and Soloway, {Mark S.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.urolonc.2012.12.003",
language = "English",
volume = "32",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Active surveillance for low-risk bladder cancer

AU - Tiu, Albert

AU - Jenkins, Lawrence C.

AU - Soloway, Mark S.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Most newly diagnosed bladder cancers present as non-muscle invasive bladder cancer (NMIBC). NMIBC is a heterogeneous disease with varying treatment options, follow-up schedules, and oncologic outcomes. We sought to review the role of active surveillance for low risk bladder cancer in the literature. Methods: A PubMed search was performed using the following keywords: active surveillance, low risk, bladder, transurethral resection of bladder tumor, cost, and quality of life. Relevant articles were reviewed and utilized. Results: Low-risk bladder cancer-defined as pTa low-grade papillary tumors-is the type of NMIBC with the most favorable oncologic outcome and which almost never progresses to muscle invasive disease or metastasizes. Bladder cancer has the highest per patient treatment costs of all cancers. One of the reasons is the high rate of recurrence. Patients with low-grade bladder tumors often experience a recurrence after primary transurethral resection. Many patients undergo multiple resections in the hospital. Conclusions: Appropriately selected patients with recurrent low-risk bladder cancer could be managed with either office fulguration or cystoscopic surveillance. Active surveillance for patients with low-risk bladder cancer avoids or delays the surgical and anesthetic risks of a TURBT, thus optimizing quality of life without compromising the patient's risk of cancer progression.

AB - Background: Most newly diagnosed bladder cancers present as non-muscle invasive bladder cancer (NMIBC). NMIBC is a heterogeneous disease with varying treatment options, follow-up schedules, and oncologic outcomes. We sought to review the role of active surveillance for low risk bladder cancer in the literature. Methods: A PubMed search was performed using the following keywords: active surveillance, low risk, bladder, transurethral resection of bladder tumor, cost, and quality of life. Relevant articles were reviewed and utilized. Results: Low-risk bladder cancer-defined as pTa low-grade papillary tumors-is the type of NMIBC with the most favorable oncologic outcome and which almost never progresses to muscle invasive disease or metastasizes. Bladder cancer has the highest per patient treatment costs of all cancers. One of the reasons is the high rate of recurrence. Patients with low-grade bladder tumors often experience a recurrence after primary transurethral resection. Many patients undergo multiple resections in the hospital. Conclusions: Appropriately selected patients with recurrent low-risk bladder cancer could be managed with either office fulguration or cystoscopic surveillance. Active surveillance for patients with low-risk bladder cancer avoids or delays the surgical and anesthetic risks of a TURBT, thus optimizing quality of life without compromising the patient's risk of cancer progression.

KW - Active surveillance

KW - Bladder cancer

KW - Cost

KW - Low risk

KW - Quality of life

KW - Transurethral resection of bladder tumor

UR - http://www.scopus.com/inward/record.url?scp=84890805727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890805727&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2012.12.003

DO - 10.1016/j.urolonc.2012.12.003

M3 - Article

AN - SCOPUS:84890805727

VL - 32

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 1

ER -